A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date2/05/25 → 1/05/27

Keywords

  • Clinical Trial
  • CA0711000

Clinical Trial Phase

  • Phase III (a & b)